Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
- To provide expanded access to RAD001 in patients with MRCC whose disease has progressed despite prior VEGF receptor tyrosine kinase inhibitor therapy, until the product is commercially available for MRCC in each participating country. - To evaluate the safety profile of RAD001 in patients with MRCC whose disease has progressed despite prior VEGF receptor tyrosine kinase inhibitor therapy
Critère d'inclusion
- Pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con inhibidor de tirosina quinasas del receptor del factor de crecimiento endotelial vascular